Skip to main content
Top
Published in: BMC Pulmonary Medicine 1/2024

Open Access 01-12-2024 | Computed Tomography | Case Report

Inflammatory myofibroblastic tumor directly invading the right first rib treated with oral steroids: a case report

Authors: Ryo Watanabe, Satoshi Ano, Norihiro Kikuchi, Michiko Saegusa, Rie Shigemasa, Yuzuru Kondo, Nobuyuki Hizawa

Published in: BMC Pulmonary Medicine | Issue 1/2024

Login to get access

Abstract

Background

We present a case of an inflammatory myofibroblastic tumor cured with a short period of steroid administration, a treatment previously unreported for such cases.

Case presentation

A 49-year-old man had a chief complaint of chest pain for more than 3 days. Computed tomography (CT) revealed a tumoral lesion suspected to have infiltrated into the right first rib and intercostal muscles, with changes in lung parenchymal density around the lesion. The maximal standardized uptake value on 18 F-fluorodeoxyglucose positron emission tomography/computed tomography was high (16.73), consistent with tumor presence. CT-guided biopsy revealed an inflammatory myofibroblastic tumor with no distant metastases. Surgery was indicated based on the disease course. However, he had received an oral steroid before the preoperative contrast-enhanced CT scan due to a history of bronchial asthma, and subsequent CT showed that the tumor shrank in size after administration; he has been recurrence-free for more than a year.

Conclusions

Surgery is still the first choice for inflammatory myofibroblastic tumors, as the disease can metastasize and relapse; however, this condition can also be cured with a short period of steroid therapy.
Literature
1.
go back to reference Khatri A, Agrawal A, Sikachi RR, Mehta D, Sahni S, Meena N. Inflammatory myofibroblastic tumor of the lung. Eur J Cardiothorac Surg. 2004;25:155–9.CrossRef Khatri A, Agrawal A, Sikachi RR, Mehta D, Sahni S, Meena N. Inflammatory myofibroblastic tumor of the lung. Eur J Cardiothorac Surg. 2004;25:155–9.CrossRef
2.
go back to reference Gleason BC, Hornick JL. Inflammatory myofibroblastic tumours: where are we now? J Clin Pathol. 2008;61:428–37.CrossRefPubMed Gleason BC, Hornick JL. Inflammatory myofibroblastic tumours: where are we now? J Clin Pathol. 2008;61:428–37.CrossRefPubMed
3.
go back to reference Cantera JE, Alfaro MP, Rafart DC, Zalazar R, Muruzabal MM, Barquín PG, et al. Inflammatory myofibroblastic tumours: a pictorial review. Insights Imaging. 2015;6:85–96.CrossRefPubMed Cantera JE, Alfaro MP, Rafart DC, Zalazar R, Muruzabal MM, Barquín PG, et al. Inflammatory myofibroblastic tumours: a pictorial review. Insights Imaging. 2015;6:85–96.CrossRefPubMed
4.
go back to reference Coffin CM, Fletcher JA. Inflammatory myofibroblastic tumour. Ed. by Fletcher CDM, Unni KK, Mertens F, World Health Organization Classification of tumours of Soft Tissue and Bone. IARC Press. Lyon. 2002;91–93. Coffin CM, Fletcher JA. Inflammatory myofibroblastic tumour. Ed. by Fletcher CDM, Unni KK, Mertens F, World Health Organization Classification of tumours of Soft Tissue and Bone. IARC Press. Lyon. 2002;91–93.
5.
go back to reference Gros L, Dei Tos AP, Jones RL, Digklia A. Inflammatory myofibroblastic tumors. J Surg Oncol. 2006;94:385–91.CrossRef Gros L, Dei Tos AP, Jones RL, Digklia A. Inflammatory myofibroblastic tumors. J Surg Oncol. 2006;94:385–91.CrossRef
6.
go back to reference Coffin CM, Watterson J, Priest JR, Dehner LP. Extrapulmonary inflammatory myofibroblastic tumor (inflammatory pseudotumor). A clinicopathologic and immunohistochemical study of 84 cases. Am J Surg Pathol. 1995;19:859–72.CrossRefPubMed Coffin CM, Watterson J, Priest JR, Dehner LP. Extrapulmonary inflammatory myofibroblastic tumor (inflammatory pseudotumor). A clinicopathologic and immunohistochemical study of 84 cases. Am J Surg Pathol. 1995;19:859–72.CrossRefPubMed
7.
go back to reference Suetsugu S, Yamamoto H, Izumi M, Takayama K, Inoue H, Nakanishi Y. [A case of rapidly growing inflammatory myofibroblastic tumor in the lung]. Nihon Kokyuki Gakkai Zasshi. 2009;47:1156–60.PubMed Suetsugu S, Yamamoto H, Izumi M, Takayama K, Inoue H, Nakanishi Y. [A case of rapidly growing inflammatory myofibroblastic tumor in the lung]. Nihon Kokyuki Gakkai Zasshi. 2009;47:1156–60.PubMed
8.
go back to reference Panigada S, Sacco O, Girosi D, Magnano GM, Tuo P, Tarantino V, et al. Corticosteroids may favor proliferation of thoracic inflammatory myofibroblastic tumors. Pediatr Pulmonol. 2014;49:E109–11.CrossRefPubMed Panigada S, Sacco O, Girosi D, Magnano GM, Tuo P, Tarantino V, et al. Corticosteroids may favor proliferation of thoracic inflammatory myofibroblastic tumors. Pediatr Pulmonol. 2014;49:E109–11.CrossRefPubMed
9.
go back to reference Jiang JY, Comsa M, Wong VCK, Mansberg R. Steroid responsive inflammatory myofibroblastic tumor of the lung evaluated by FDG PET/CT imaging. Radiol Case Rep. 2022;17:907–10.CrossRefPubMedPubMedCentral Jiang JY, Comsa M, Wong VCK, Mansberg R. Steroid responsive inflammatory myofibroblastic tumor of the lung evaluated by FDG PET/CT imaging. Radiol Case Rep. 2022;17:907–10.CrossRefPubMedPubMedCentral
10.
go back to reference Biswas R, Halder A, Gangopadhyay M, Biswas D. Inflammatory myofibroblastic tumor of maxillary sinus successfully treated with radiotherapy and corticosteroid: report of a rare case. J Egypt Natl Canc Inst. 2020;32:26.CrossRefPubMed Biswas R, Halder A, Gangopadhyay M, Biswas D. Inflammatory myofibroblastic tumor of maxillary sinus successfully treated with radiotherapy and corticosteroid: report of a rare case. J Egypt Natl Canc Inst. 2020;32:26.CrossRefPubMed
11.
go back to reference Navinan MR, Liyanage I, Herath S, Yudhishdran J, Shivanthan C, Beneragama D, et al. Inoperable inflammatory myofibroblastic tumour of the para-nasal sinuses and orbit with recurrence responding to methotrexate and prednisolone: a case report. BMC Res Notes. 2015;8:27.CrossRefPubMedPubMedCentral Navinan MR, Liyanage I, Herath S, Yudhishdran J, Shivanthan C, Beneragama D, et al. Inoperable inflammatory myofibroblastic tumour of the para-nasal sinuses and orbit with recurrence responding to methotrexate and prednisolone: a case report. BMC Res Notes. 2015;8:27.CrossRefPubMedPubMedCentral
12.
go back to reference Shatzel J, Wooten K, Ankola A, Cheney RT, Morrison CD, Skitzki JJ. Inflammatory myofibroblastic tumor of the mesentery: a clinical dilemma. Int J Clin Oncol. 2012;17:380–4.CrossRefPubMed Shatzel J, Wooten K, Ankola A, Cheney RT, Morrison CD, Skitzki JJ. Inflammatory myofibroblastic tumor of the mesentery: a clinical dilemma. Int J Clin Oncol. 2012;17:380–4.CrossRefPubMed
13.
go back to reference Pearson ADJ, Barry E, Mossé YP, Ligas F, Bird N, de Rojas T, et al. Second paediatric Strategy Forum for anaplastic lymphoma kinase (ALK) inhibition in paediatric malignancies: ACCELERATE in collaboration with the European Medicines Agency with the participation of the Food and Drug Administration. Eur J Cancer. 2021;157:198–213.CrossRefPubMed Pearson ADJ, Barry E, Mossé YP, Ligas F, Bird N, de Rojas T, et al. Second paediatric Strategy Forum for anaplastic lymphoma kinase (ALK) inhibition in paediatric malignancies: ACCELERATE in collaboration with the European Medicines Agency with the participation of the Food and Drug Administration. Eur J Cancer. 2021;157:198–213.CrossRefPubMed
14.
go back to reference Gambacorti-Passerini C, Orlov S, Zhang L, Braiteh F, Huang H, Esaki T, et al. Long-term effects of crizotinib in ALK-positive tumors (excluding NSCLC): a phase 1b open-label study. Am J Hematol. 2018;93:607–14.CrossRefPubMedPubMedCentral Gambacorti-Passerini C, Orlov S, Zhang L, Braiteh F, Huang H, Esaki T, et al. Long-term effects of crizotinib in ALK-positive tumors (excluding NSCLC): a phase 1b open-label study. Am J Hematol. 2018;93:607–14.CrossRefPubMedPubMedCentral
Metadata
Title
Inflammatory myofibroblastic tumor directly invading the right first rib treated with oral steroids: a case report
Authors
Ryo Watanabe
Satoshi Ano
Norihiro Kikuchi
Michiko Saegusa
Rie Shigemasa
Yuzuru Kondo
Nobuyuki Hizawa
Publication date
01-12-2024
Publisher
BioMed Central
Published in
BMC Pulmonary Medicine / Issue 1/2024
Electronic ISSN: 1471-2466
DOI
https://doi.org/10.1186/s12890-024-02873-6

Other articles of this Issue 1/2024

BMC Pulmonary Medicine 1/2024 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.